Your browser doesn't support javascript.
loading
A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.
Boyle, Theresa A; Quinn, Gwendolyn P; Schabath, Matthew B; Muñoz-Antonia, Teresita; Saller, James J; Duarte, Luisa F; Hair, Laura S; Teer, Jamie K; Chiang, Derek Y; Leary, Rebecca; Wong, Connie C; Savchenko, Alexander; Singh, Angad P; Charette, LaSalette; Mendell, Kate; Gorgun, Gullu; Antonia, Scott J; Chiappori, Alberto A; Creelan, Benjamin C; Gray, Jhanelle E; Haura, Eric B.
Affiliation
  • Boyle TA; Department of Oncologic Science, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
  • Quinn GP; Anatomic Pathology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Schabath MB; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Muñoz-Antonia T; Department of Ob-Gyn, New York University School of Medicine, New York, NY, USA.
  • Saller JJ; Department of Oncologic Science, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
  • Duarte LF; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Hair LS; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Teer JK; Department of Oncologic Science, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
  • Chiang DY; Tumor Biology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Leary R; Anatomic Pathology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Wong CC; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Savchenko A; District 12 Medical Examiner's Office, Sarasota, FL, USA.
  • Singh AP; Department of Oncologic Science, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
  • Charette L; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Mendell K; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Gorgun G; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Antonia SJ; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Chiappori AA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Creelan BC; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Gray JE; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Haura EB; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Cancer Med ; 9(1): 225-237, 2020 01.
Article in En | MEDLINE | ID: mdl-31747139
ABSTRACT

BACKGROUND:

For the advancement of cancer research, the collection of tissue specimens from drug-resistant tumors after targeted therapy is crucial. Although patients with lung cancer are often provided targeted therapy, post-therapy specimens are not routinely collected due to the risks of collection, limiting the study of targeted therapy resistance mechanisms. Posthumous rapid tissue donation (RTD) is an expedient collection process that provides an opportunity to understand treatment-resistant lung cancers.

METHODS:

Consent to participate in the thoracic RTD protocol was obtained during patient care. When death occurred, tumor and paired non-tumor, cytology, and blood specimens were collected within 48 hours and preserved as formalin-fixed and frozen specimens. Tissue sections were evaluated with hematoxylin and eosin staining and immunohistochemistry (IHC) against multiple biomarkers, including various programmed death ligand 1 (PD-L1) clones. Next-generation sequencing was performed on 13 specimens from 5 patients.

RESULTS:

Postmortem specimens (N = 180) were well preserved from 9 patients with lung cancer. PD-L1 IHC revealed heterogeneity within and between tumors. An AGK-BRAF fusion was newly identified in tumor from a donor with a known echinoderm microtubule-associated protein-like 4 to anaplastic lymphoma kinase (EML4-ALK) fusion and history of anaplastic lymphoma kinase (ALK) inhibitor therapy. RNA expression analysis revealed a clonal genetic origin of metastatic cancer cells.

CONCLUSIONS:

Post-therapy specimens demonstrated PD-L1 heterogeneity and an acyl glycerol kinase to B-rapidly accelerated fibrosarcoma (AGK-BRAF) fusion in a patient with an EML4-ALK-positive lung adenocarcinoma as a potential resistance mechanism to ALK inhibitor therapy. Rapid tissue donation collection of postmortem tissue from lung cancer patients is a novel approach to cancer research that enables studies of molecular evolution and drug resistance.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tissue and Organ Procurement / Biomarkers, Tumor / Drug Resistance, Neoplasm / Community-Based Participatory Research / Adenocarcinoma of Lung / Lung Neoplasms Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Cancer Med Year: 2020 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tissue and Organ Procurement / Biomarkers, Tumor / Drug Resistance, Neoplasm / Community-Based Participatory Research / Adenocarcinoma of Lung / Lung Neoplasms Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Cancer Med Year: 2020 Document type: Article Affiliation country: Estados Unidos